Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Rivaroxaban (ATC-Code: B01AF01 - in allen Wirkstärken außer 2,5 mg je abgeteilte orale Darreichungsform).

Conclusion of a non-exclusive discount contract pursuant to Section 130a, Paragraph 8, SGB V for medicinal products with the active substance Rivaroxaban (ATC Code: B01AF01 - in all strengths except 2.5 mg per divided oral dosage form) within the period from 01.09.2026 to 31.08.2028 with the possibility of concluding the contract at any time during the term ("open-house model").